{ "company_number": "07373967", "name": "Tasmia Pharmaceuticals Limited", "url": "/company/07373967", "status": "Active", "is_active": true, "company_type": "Private Limited Company", "incorporated_on": "2010-09-13", "dissolved_on": null, "sic_codes": [ { "code": "86900", "description": "Other human health activities", "section": "Q", "section_name": "Human health and social work activities", "url": "/sic/86900" } ], "registered_address": { "id": 1502676, "url": "/address/1502676", "line1": "116 STAPLETON ROAD", "line2": "", "post_town": "BRISTOL", "county": "", "country": "", "postcode": "BS5 0PS" }, "companies_house_url": "https://find-and-update.company-information.service.gov.uk/company/07373967", "previous_names": [], "care_of": "", "po_box": "", "country_of_origin": "United Kingdom", "accounts": { "next_due": "2027-01-31", "last_made_up": "2025-04-30", "category": "TOTAL EXEMPTION FULL", "filings": [ { "url": "/company/07373967/accounts/2025-04-30", "pdf_url": "/company/07373967/accounts/2025-04-30.pdf", "made_up_date": "2025-04-30", "period_start": "2024-05-01", "period_end": "2025-04-30", "entity_name": "Tasmia Pharmaceuticals Limited", "dormant": false, "average_employees": "5.00", "tangible_fixed_assets": "180410.00", "debtors": "51777.00", "cash_bank_in_hand": "5062.00", "current_assets": "92395.00", "creditors_due_within_one_year": "132773.00", "creditors_due_after_one_year": null, "net_current_assets_liabilities": "-40378.00", "total_assets_less_current_liabilities": "140032.00", "net_assets_liabilities": "136698.00", "called_up_share_capital": "2.00", "profit_loss_account_reserve": "136696.00", "shareholder_funds": "2.00", "turnover": null, "other_operating_income": null, "cost_sales": null, "gross_profit_loss": null, "administrative_expenses": null, "raw_materials_consumables": null, "staff_costs": "67000.00", "depreciation_written_off": null, "other_operating_charges": null, "operating_profit_loss": null, "profit_before_tax": null, "tax_on_profit": null, "profit_loss_for_period": "29055.00", "file_type": "html", "parse_error": "", "source_zip": "Accounts_Monthly_Data-October2025.zip" }, { "url": "/company/07373967/accounts/2024-04-30", "pdf_url": "/company/07373967/accounts/2024-04-30.pdf", "made_up_date": "2024-04-30", "period_start": "2023-05-01", "period_end": "2024-04-30", "entity_name": "Tasmia Pharmaceuticals Limited", "dormant": false, "average_employees": "6.00", "tangible_fixed_assets": "180483.00", "debtors": "44831.00", "cash_bank_in_hand": "10062.00", "current_assets": "89343.00", "creditors_due_within_one_year": "119907.00", "creditors_due_after_one_year": null, "net_current_assets_liabilities": "-30564.00", "total_assets_less_current_liabilities": "149919.00", "net_assets_liabilities": "136586.00", "called_up_share_capital": "2.00", "profit_loss_account_reserve": "136584.00", "shareholder_funds": "2.00", "turnover": null, "other_operating_income": null, "cost_sales": null, "gross_profit_loss": null, "administrative_expenses": null, "raw_materials_consumables": null, "staff_costs": "53377.00", "depreciation_written_off": null, "other_operating_charges": null, "operating_profit_loss": null, "profit_before_tax": null, "tax_on_profit": null, "profit_loss_for_period": "36053.00", "file_type": "html", "parse_error": "", "source_zip": "Accounts_Monthly_Data-January2025.zip" }, { "url": "/company/07373967/accounts/2023-04-30", "pdf_url": "/company/07373967/accounts/2023-04-30.pdf", "made_up_date": "2023-04-30", "period_start": "2022-11-01", "period_end": "2023-04-30", "entity_name": "Tasmia Pharmaceuticals Limited", "dormant": false, "average_employees": "7.00", "tangible_fixed_assets": "180568.00", "debtors": "35810.00", "cash_bank_in_hand": "630.00", "current_assets": "76440.00", "creditors_due_within_one_year": "123142.00", "creditors_due_after_one_year": null, "net_current_assets_liabilities": "-46702.00", "total_assets_less_current_liabilities": "133866.00", "net_assets_liabilities": "110533.00", "called_up_share_capital": "2.00", "profit_loss_account_reserve": "110531.00", "shareholder_funds": "2.00", "turnover": null, "other_operating_income": null, "cost_sales": null, "gross_profit_loss": null, "administrative_expenses": null, "raw_materials_consumables": null, "staff_costs": "25076.00", "depreciation_written_off": null, "other_operating_charges": null, "operating_profit_loss": null, "profit_before_tax": null, "tax_on_profit": null, "profit_loss_for_period": "-22157.00", "file_type": "html", "parse_error": "", "source_zip": "Accounts_Monthly_Data-December2023.zip" }, { "url": "/company/07373967/accounts/2022-10-31", "pdf_url": "/company/07373967/accounts/2022-10-31.pdf", "made_up_date": "2022-10-31", "period_start": "2021-11-01", "period_end": "2022-10-31", "entity_name": "Tasmia Pharmaceuticals Limited", "dormant": false, "average_employees": "10.00", "tangible_fixed_assets": "180614.00", "debtors": "71502.00", "cash_bank_in_hand": "630.00", "current_assets": "112132.00", "creditors_due_within_one_year": "131723.00", "creditors_due_after_one_year": null, "net_current_assets_liabilities": "-19591.00", "total_assets_less_current_liabilities": "161023.00", "net_assets_liabilities": "132690.00", "called_up_share_capital": "2.00", "profit_loss_account_reserve": "132688.00", "shareholder_funds": "2.00", "turnover": null, "other_operating_income": null, "cost_sales": null, "gross_profit_loss": null, "administrative_expenses": null, "raw_materials_consumables": null, "staff_costs": "49890.00", "depreciation_written_off": null, "other_operating_charges": null, "operating_profit_loss": null, "profit_before_tax": null, "tax_on_profit": null, "profit_loss_for_period": "8205.00", "file_type": "html", "parse_error": "", "source_zip": "Accounts_Monthly_Data-July2023.zip" }, { "url": "/company/07373967/accounts/2021-10-31", "pdf_url": "/company/07373967/accounts/2021-10-31.pdf", "made_up_date": "2021-10-31", "period_start": "2020-11-01", "period_end": "2021-10-31", "entity_name": "Tasmia Pharmaceuticals Limited", "dormant": false, "average_employees": "6.00", "tangible_fixed_assets": "180723.00", "debtors": "37627.00", "cash_bank_in_hand": "2104.00", "current_assets": "67790.00", "creditors_due_within_one_year": "85695.00", "creditors_due_after_one_year": null, "net_current_assets_liabilities": "-17905.00", "total_assets_less_current_liabilities": "162818.00", "net_assets_liabilities": "124485.00", "called_up_share_capital": "2.00", "profit_loss_account_reserve": "124483.00", "shareholder_funds": "2.00", "turnover": null, "other_operating_income": null, "cost_sales": null, "gross_profit_loss": null, "administrative_expenses": null, "raw_materials_consumables": null, "staff_costs": "101599.00", "depreciation_written_off": null, "other_operating_charges": null, "operating_profit_loss": null, "profit_before_tax": null, "tax_on_profit": null, "profit_loss_for_period": "15054.00", "file_type": "html", "parse_error": "", "source_zip": "Accounts_Monthly_Data-June2022.zip" }, { "url": "/company/07373967/accounts/2020-10-31", "pdf_url": "/company/07373967/accounts/2020-10-31.pdf", "made_up_date": "2020-10-31", "period_start": "2019-11-01", "period_end": "2020-10-31", "entity_name": "Tasmia Pharmaceuticals Limited", "dormant": false, "average_employees": "6.00", "tangible_fixed_assets": "180851.00", "debtors": "46760.00", "cash_bank_in_hand": "8028.00", "current_assets": "82847.00", "creditors_due_within_one_year": "102267.00", "creditors_due_after_one_year": null, "net_current_assets_liabilities": "-19420.00", "total_assets_less_current_liabilities": "161431.00", "net_assets_liabilities": "111431.00", "called_up_share_capital": "2.00", "profit_loss_account_reserve": "111429.00", "shareholder_funds": "2.00", "turnover": null, "other_operating_income": null, "cost_sales": null, "gross_profit_loss": null, "administrative_expenses": null, "raw_materials_consumables": null, "staff_costs": "92460.00", "depreciation_written_off": null, "other_operating_charges": null, "operating_profit_loss": null, "profit_before_tax": null, "tax_on_profit": null, "profit_loss_for_period": "39838.00", "file_type": "html", "parse_error": "", "source_zip": "Accounts_Monthly_Data-May2021.zip" }, { "url": "/company/07373967/accounts/2019-10-31", "pdf_url": "/company/07373967/accounts/2019-10-31.pdf", "made_up_date": "2019-10-31", "period_start": "2018-11-01", "period_end": "2019-10-31", "entity_name": "Tasmia Pharmaceuticals Limited", "dormant": false, "average_employees": "6.00", "tangible_fixed_assets": "181001.00", "debtors": "35906.00", "cash_bank_in_hand": "9889.00", "current_assets": "76103.00", "creditors_due_within_one_year": "183326.00", "creditors_due_after_one_year": null, "net_current_assets_liabilities": "-107223.00", "total_assets_less_current_liabilities": "73778.00", "net_assets_liabilities": "73778.00", "called_up_share_capital": "2.00", "profit_loss_account_reserve": "73591.00", "shareholder_funds": "2.00", "turnover": null, "other_operating_income": null, "cost_sales": null, "gross_profit_loss": null, "administrative_expenses": null, "raw_materials_consumables": null, "staff_costs": "77343.00", "depreciation_written_off": null, "other_operating_charges": null, "operating_profit_loss": null, "profit_before_tax": null, "tax_on_profit": null, "profit_loss_for_period": "39048.00", "file_type": "html", "parse_error": "", "source_zip": "Accounts_Monthly_Data-June2020.zip" }, { "url": "/company/07373967/accounts/2018-10-31", "pdf_url": "/company/07373967/accounts/2018-10-31.pdf", "made_up_date": "2018-10-31", "period_start": "2018-10-31", "period_end": "2018-10-31", "entity_name": "Tasmia Pharmaceuticals Limited", "dormant": null, "average_employees": null, "tangible_fixed_assets": "181178.00", "debtors": "41506.00", "cash_bank_in_hand": "67.00", "current_assets": "46359.00", "creditors_due_within_one_year": null, "creditors_due_after_one_year": null, "net_current_assets_liabilities": "144632.00", "total_assets_less_current_liabilities": null, "net_assets_liabilities": "36546.00", "called_up_share_capital": null, "profit_loss_account_reserve": null, "shareholder_funds": "2.00", "turnover": null, "other_operating_income": null, "cost_sales": null, "gross_profit_loss": null, "administrative_expenses": null, "raw_materials_consumables": null, "staff_costs": null, "depreciation_written_off": null, "other_operating_charges": null, "operating_profit_loss": null, "profit_before_tax": null, "tax_on_profit": null, "profit_loss_for_period": null, "file_type": "html", "parse_error": "", "source_zip": "Accounts_Monthly_Data-April2019.zip" }, { "url": "/company/07373967/accounts/2017-10-31", "pdf_url": "/company/07373967/accounts/2017-10-31.pdf", "made_up_date": "2017-10-31", "period_start": "2017-10-31", "period_end": "2017-10-31", "entity_name": "Tasmia Pharmaceuticals Limited", "dormant": null, "average_employees": null, "tangible_fixed_assets": "181386.00", "debtors": "30954.00", "cash_bank_in_hand": "328.00", "current_assets": "34064.00", "creditors_due_within_one_year": null, "creditors_due_after_one_year": null, "net_current_assets_liabilities": "146254.00", "total_assets_less_current_liabilities": null, "net_assets_liabilities": "35132.00", "called_up_share_capital": null, "profit_loss_account_reserve": null, "shareholder_funds": "2.00", "turnover": null, "other_operating_income": null, "cost_sales": null, "gross_profit_loss": null, "administrative_expenses": null, "raw_materials_consumables": null, "staff_costs": null, "depreciation_written_off": null, "other_operating_charges": null, "operating_profit_loss": null, "profit_before_tax": null, "tax_on_profit": null, "profit_loss_for_period": null, "file_type": "html", "parse_error": "", "source_zip": "Accounts_Monthly_Data-June2018.zip" }, { "url": "/company/07373967/accounts/2016-10-31", "pdf_url": "/company/07373967/accounts/2016-10-31.pdf", "made_up_date": "2016-10-31", "period_start": "2016-10-31", "period_end": "2016-10-31", "entity_name": "Tasmia Pharmaceuticals Limited", "dormant": false, "average_employees": null, "tangible_fixed_assets": "181631.00", "debtors": null, "cash_bank_in_hand": "60.00", "current_assets": "45933.00", "creditors_due_within_one_year": "197652.00", "creditors_due_after_one_year": null, "net_current_assets_liabilities": "151719.00", "total_assets_less_current_liabilities": null, "net_assets_liabilities": null, "called_up_share_capital": "2.00", "profit_loss_account_reserve": "29910.00", "shareholder_funds": "29912.00", "turnover": null, "other_operating_income": null, "cost_sales": null, "gross_profit_loss": null, "administrative_expenses": null, "raw_materials_consumables": null, "staff_costs": null, "depreciation_written_off": null, "other_operating_charges": null, "operating_profit_loss": null, "profit_before_tax": null, "tax_on_profit": null, "profit_loss_for_period": null, "file_type": "html", "parse_error": "", "source_zip": "Accounts_Monthly_Data-January2017.zip" }, { "url": "/company/07373967/accounts/2015-10-31", "pdf_url": "/company/07373967/accounts/2015-10-31.pdf", "made_up_date": "2015-10-31", "period_start": "2015-10-31", "period_end": "2015-10-31", "entity_name": "Tasmia Pharmaceuticals Limited", "dormant": false, "average_employees": null, "tangible_fixed_assets": "181919.00", "debtors": null, "cash_bank_in_hand": "4457.00", "current_assets": "16217.00", "creditors_due_within_one_year": "163412.00", "creditors_due_after_one_year": null, "net_current_assets_liabilities": "147195.00", "total_assets_less_current_liabilities": null, "net_assets_liabilities": null, "called_up_share_capital": "2.00", "profit_loss_account_reserve": "34722.00", "shareholder_funds": "34724.00", "turnover": null, "other_operating_income": null, "cost_sales": null, "gross_profit_loss": null, "administrative_expenses": null, "raw_materials_consumables": null, "staff_costs": null, "depreciation_written_off": null, "other_operating_charges": null, "operating_profit_loss": null, "profit_before_tax": null, "tax_on_profit": null, "profit_loss_for_period": null, "file_type": "html", "parse_error": "", "source_zip": "Accounts_Monthly_Data-May2016.zip" }, { "url": "/company/07373967/accounts/2014-10-31", "pdf_url": "/company/07373967/accounts/2014-10-31.pdf", "made_up_date": "2014-10-31", "period_start": "2014-10-31", "period_end": "2014-10-31", "entity_name": "Tasmia Pharmaceuticals Limited", "dormant": false, "average_employees": null, "tangible_fixed_assets": "182257.00", "debtors": null, "cash_bank_in_hand": "6410.00", "current_assets": "31840.00", "creditors_due_within_one_year": "186616.00", "creditors_due_after_one_year": null, "net_current_assets_liabilities": "154776.00", "total_assets_less_current_liabilities": null, "net_assets_liabilities": null, "called_up_share_capital": "2.00", "profit_loss_account_reserve": "27479.00", "shareholder_funds": "27481.00", "turnover": null, "other_operating_income": null, "cost_sales": null, "gross_profit_loss": null, "administrative_expenses": null, "raw_materials_consumables": null, "staff_costs": null, "depreciation_written_off": null, "other_operating_charges": null, "operating_profit_loss": null, "profit_before_tax": null, "tax_on_profit": null, "profit_loss_for_period": null, "file_type": "html", "parse_error": "", "source_zip": "Accounts_Monthly_Data-July2015.zip" }, { "url": "/company/07373967/accounts/2013-10-31", "pdf_url": "/company/07373967/accounts/2013-10-31.pdf", "made_up_date": "2013-10-31", "period_start": "2013-10-31", "period_end": "2013-10-31", "entity_name": "Tasmia Pharmaceuticals Limited", "dormant": false, "average_employees": null, "tangible_fixed_assets": "182656.00", "debtors": null, "cash_bank_in_hand": "452.00", "current_assets": "29050.00", "creditors_due_within_one_year": "197322.00", "creditors_due_after_one_year": null, "net_current_assets_liabilities": "168272.00", "total_assets_less_current_liabilities": null, "net_assets_liabilities": null, "called_up_share_capital": "2.00", "profit_loss_account_reserve": "14382.00", "shareholder_funds": "14384.00", "turnover": null, "other_operating_income": null, "cost_sales": null, "gross_profit_loss": null, "administrative_expenses": null, "raw_materials_consumables": null, "staff_costs": null, "depreciation_written_off": null, "other_operating_charges": null, "operating_profit_loss": null, "profit_before_tax": null, "tax_on_profit": null, "profit_loss_for_period": null, "file_type": "html", "parse_error": "", "source_zip": "Accounts_Monthly_Data-June2014.zip" }, { "url": "/company/07373967/accounts/2012-10-31", "pdf_url": "/company/07373967/accounts/2012-10-31.pdf", "made_up_date": "2012-10-31", "period_start": "2012-10-31", "period_end": "2012-10-31", "entity_name": "Tasmia Pharmaceuticals Limited", "dormant": false, "average_employees": null, "tangible_fixed_assets": "182045.00", "debtors": "37265.00", "cash_bank_in_hand": "24017.00", "current_assets": "74108.00", "creditors_due_within_one_year": "241843.00", "creditors_due_after_one_year": null, "net_current_assets_liabilities": "-167735.00", "total_assets_less_current_liabilities": "14310.00", "net_assets_liabilities": "14310.00", "called_up_share_capital": "2.00", "profit_loss_account_reserve": "14308.00", "shareholder_funds": "14310.00", "turnover": null, "other_operating_income": null, "cost_sales": null, "gross_profit_loss": null, "administrative_expenses": null, "raw_materials_consumables": null, "staff_costs": null, "depreciation_written_off": null, "other_operating_charges": null, "operating_profit_loss": null, "profit_before_tax": null, "tax_on_profit": null, "profit_loss_for_period": null, "file_type": "html", "parse_error": "", "source_zip": "Accounts_Monthly_Data-March2013.zip" }, { "url": "/company/07373967/accounts/2011-10-31", "pdf_url": "/company/07373967/accounts/2011-10-31.pdf", "made_up_date": "2011-10-31", "period_start": "2011-10-31", "period_end": "2011-10-31", "entity_name": "Tasmia Pharmaceuticals Limited", "dormant": false, "average_employees": null, "tangible_fixed_assets": "205847.00", "debtors": "25740.00", "cash_bank_in_hand": "918.00", "current_assets": "45114.00", "creditors_due_within_one_year": null, "creditors_due_after_one_year": null, "net_current_assets_liabilities": "-195007.00", "total_assets_less_current_liabilities": "10840.00", "net_assets_liabilities": "10840.00", "called_up_share_capital": "2.00", "profit_loss_account_reserve": "10838.00", "shareholder_funds": "10840.00", "turnover": null, "other_operating_income": null, "cost_sales": null, "gross_profit_loss": null, "administrative_expenses": null, "raw_materials_consumables": null, "staff_costs": null, "depreciation_written_off": null, "other_operating_charges": null, "operating_profit_loss": null, "profit_before_tax": null, "tax_on_profit": null, "profit_loss_for_period": null, "file_type": "xml", "parse_error": "", "source_zip": "Accounts_Monthly_Data-June2012.zip" } ], "pdf_only_filings": [], "filing_history_url": "https://find-and-update.company-information.service.gov.uk/company/07373967/filing-history" }, "confirmation_statement": { "next_due": "2027-07-14", "last_made_up": "2026-06-30" }, "officers": [ { "name": "YASIN, Nadeem Mohamed", "person_url": "/person/5532728", "role": "director", "appointed_on": "2010-09-13", "resigned_on": null, "nationality": "British", "occupation": "", "source": "stream", "retrieved_at": "2026-07-08T16:57:15+00:00" } ], "psc": [ { "name": "Mr Nadeem Mohamed Yasin", "kind": "individual-person-with-significant-control", "person_url": "/person/3550111", "controlling_company_url": null, "natures_of_control": [ "ownership-of-shares-75-to-100-percent", "ownership-of-shares-75-to-100-percent-as-firm", "voting-rights-75-to-100-percent", "voting-rights-75-to-100-percent-as-firm" ], "notified_on": "2016-07-01", "ceased_on": null, "nationality": "British", "country_of_residence": "England", "source": "snapshot" } ], "external_links": [], "provenance": { "source": "snapshot", "first_seen_at": "2026-07-05T12:35:35.811816+00:00", "last_seen_snapshot": "2026-08-01", "retrieved_at": "2026-08-14T22:43:52.697050+00:00" }, "licence": "Open Government Licence v3.0", "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/", "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: Companies House." }